HOXC-AS1: A Key Biomarker for Prognosis and Immunotherapy in Lung Adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High HOXC-AS1 expression is linked to poor outcomes in lung adenocarcinoma (LUAD). This study suggests HOXC-AS1 may serve as a biomarker for prognosis and immunotherapy response in LUAD patients.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- The role of HOXC antisense RNA 1 (HOXC-AS1) in lung adenocarcinoma (LUAD) is not well understood.
- Investigating novel molecular markers is crucial for improving LUAD diagnosis and treatment.
Purpose Of The Study
- To investigate the association between HOXC-AS1 expression levels and clinical outcomes in LUAD.
- To explore the potential of HOXC-AS1 as a prognostic biomarker in LUAD.
Main Methods
- Bioinformatic analysis of HOXC-AS1 expression in relation to clinical features, survival, and immune infiltration in LUAD.
- Quantitative reverse transcription PCR (qRT-PCR) to measure HOXC-AS1 levels in LUAD cell lines.
Main Results
- HOXC-AS1 expression was significantly elevated in LUAD tissues and cell lines compared to normal controls.
- Higher HOXC-AS1 levels correlated with decreased overall survival and were an independent predictor of poor prognosis in LUAD patients.
- HOXC-AS1 expression was associated with altered immune cell infiltration and implicated in pathways like neuroactive ligand-receptor interaction.
Conclusions
- Elevated HOXC-AS1 expression is strongly associated with adverse outcomes in LUAD, including reduced survival and immune cell infiltration.
- HOXC-AS1 shows potential as a valuable biomarker for predicting LUAD patient prognosis and response to immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
